Mizuho Recommends Buying CVS (CVS) on Today's Weakness, Driven by Retail
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
CVS Health (CVS) Model Not Broken, Buy on Weakness - Guggenheim
November 8, 2016 8:50 AM ESTGuggenheim analyst John Heinbockel said at flat 2017 at CVS Health (NYSE: CVS) doesn't mean the model is broken. He said patient, value investors should find the shares compelling..
Heinbocke commented, "With the shares off 15% pre-market (vs. 2% decline in the S&P), a... More
CVS Health (CVS) Q3 Solid But Guidance Well Behind - Leerink
November 8, 2016 8:42 AM ESTLeerink Partners analyst David Larsen weighed in on CVS Health (NYSE: CVS) following solid Q3 results but disappointing guidance which has the stock down 15.3%.
Larsen commented, "This morning CVS reported 3Q:16 earnings. While earnings in the quarter were solid, guidance was disappointing.... More
Walgreens Boots Alliance (WBA) Trades Lower in Sympathy with CVS Health (CVS)
November 8, 2016 7:47 AM ESTWalgreens Boots Alliance (NASDAQ: WBA) was poised to open lower Tuesday morning as shares fell in sympathy with CVS Health (NYSE: CVS).
CVS declined 16% after reporting Q3 results and guidance that disappointed investors.
CVS Health (CVS) Tops Q3 EPS by 7c; Trims, Narrows FY16 EPS Outlook
November 8, 2016 6:56 AM ESTCVS Health (NYSE: CVS) reported Q3 EPS of $1.64, $0.07 better than the analyst estimate of $1.57. Revenue for the quarter came in at $44.6 billion versus the consensus estimate of $45.29 billion.
CVS noted, Adjusted EPS excludes $197 million and $160 million of intangible asset amortization for the three months ended... More
